You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Novel CO2 Gas Sensors for Autonomous Measurement of Ocean Carbon

    SBC: DIOXIDE MATERIALS, INC.            Topic: 82

    The objective of the proposed work is to determine whether Dioxide Materials' miniature C02 sensors have the potential to be adapted for autonomous measurement of ocean carbon. The existing sensors have many advantages for measurements of ocean carbon. They are much smaller and less costly than the existing sensors, work with much smaller gas samples, and use much less power. The sensors were d ...

    SBIR Phase I 2014 Department of CommerceNational Oceanic and Atmospheric Administration
  2. Self-Contained Sub-Centimeter Positioning Platform

    SBC: TRUNAV LLC            Topic: 81

    The goal of this project is to develop, implement, and experimentally validate a new Differential Global Navigation Satellite System (DGNSS) capable of providing sub-centimeter positioning accuracy for quasi-static scientific, mapping, and survey applications. The main feature of the proposed DGNSS solution is that it leverages GNSS reference data from existing NOAA's Continuously Operational Ref ...

    SBIR Phase I 2014 Department of CommerceNational Oceanic and Atmospheric Administration
  3. A Novel Substrate to Amplify Growth Factor Impact on hPSC Differentiation

    SBC: PRIMORIGEN BIOSCIENCES INC.            Topic: 300

    DESCRIPTION provided by applicant Primorigen Biosciences R Project Abstract Primorigen will use SBIR funds to develop a paradigm changing technology for expansion and directed differentiation of human pluripotent stem cells hPSCs using a novel peptide that dramatically reduces costs by amplifying the impact of endogenous growth factors and minimizing the need for exogenous growth factors Th ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain

    SBC: SCARAB GENOMICS, LLC            Topic: NIAID

    DESCRIPTION provided by applicant CRM is an inactive form of diphtheria toxin that when conjugated to a vaccine antigen enhances immunity to generate long lasting vaccination against the antigen Conjugate vaccines containing CRM are common and there are currently seven CRM containing conjugate vaccines on the market The top selling vaccine the CRM containing conjugate vaccine P ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Clinically Viable Pattern Recognition Embedded System

    SBC: Coapt LLC            Topic: NICHD

    DESCRIPTION provided by applicant Pattern recognition PR myoelectric control systems can dramatically improve an amputee patientandapos s control of a powered prosthesis but they have not been made commercially available Coapt LLC is a start up stage company that has initiated a controlled commercial release of PR myoelectric control for the benefit of upper limb amputees The controlle ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. IntelliWheels: The Automatic Transmission for Manually Propelled Wheelchairs

    SBC: IntelliWheels, Inc.            Topic: 22

    DESCRIPTION provided by applicant IntelliWheels automatic gear shifting wheels represent a significant paradigm shift as the first ultra light affordable and intuitive way to mke pushing a wheelchair easier The manual wheelchair user mWCU still pushes the hand rims in any direction however the hand rims drive the transmissions located in each wheel hub which in turn drive the wheels ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a novel highly effective influenza vaccine

    SBC: Flugen, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Widespread antibiotic use has accelerated S aureus resistance to almost all marketed antibiotic classes including beta lactams fluoroquinolones macrolides aminoglycosides tetracyclines as well as the newer linezolid and daptomycin Methicillin resistant S aureus MRSA is an increasing public health threat with deaths from MRSA infections already compar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. MASS PRODUCTION OF PERSONALIZED HUMAN ENGINEERED HEART TISSUES

    SBC: Invivosciences, Inc.            Topic: 200

    DESCRIPTION provided by applicant Cardiomyopathy has various forms including hypertrophic cardiomyopathy HCM in prevalence could cause sudden cardiac death in athletes Dilated Cardiomyopathy DCM in prevalence results in an enlarge left ventricle Arrhythmogenic Right Ventricular Dysplasia Cardiomyopathy ARVD C in prevalence causes cardiac fibrosis Yearly over $ ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government